Dnca Finance Has $1.64 Million Stake in Eli Lilly and Company $LLY

Dnca Finance lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 74.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,100 shares of the company’s stock after selling 6,100 shares during the period. Dnca Finance’s holdings in Eli Lilly and Company were worth $1,637,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of LLY. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company during the first quarter valued at approximately $27,000. Sumitomo Mitsui Financial Group Inc. acquired a new stake in Eli Lilly and Company in the second quarter worth $27,000. Financial Gravity Companies Inc. bought a new position in shares of Eli Lilly and Company during the second quarter worth $31,000. Bare Financial Services Inc grew its holdings in shares of Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 29 shares during the period. Finally, Blume Capital Management Inc. grew its holdings in shares of Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after buying an additional 14 shares during the period. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

LLY has been the topic of several research analyst reports. The Goldman Sachs Group raised their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research note on Friday, October 10th. BMO Capital Markets set a $1,200.00 price target on Eli Lilly and Company in a report on Thursday. Loop Capital set a $950.00 price target on Eli Lilly and Company in a research report on Monday, November 10th. HSBC boosted their price objective on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Finally, Daiwa America downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,087.32.

Eli Lilly and Company Stock Down 0.5%

LLY stock opened at $1,009.26 on Friday. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The stock has a market capitalization of $954.13 billion, a P/E ratio of 49.38, a P/E/G ratio of 1.12 and a beta of 0.37. The business has a 50-day moving average of $918.84 and a 200-day moving average of $809.74. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.Eli Lilly and Company’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.